We have previously shown that a subgroup of 10% to 15% of MM patients express IL-32 and that high IL-32 expression in patients associates with reduced progression-free survival (Zahoor et al., 2017) (Figures S6A and S6B). The gene discussed is IL32; the disease is Miyoshi myopathy.